Earnings summaries and quarterly performance for NASDAQ.
Executive leadership at NASDAQ.
Adena Friedman
Detailed
Chair and Chief Executive Officer
CEO
BP
Bradley Peterson
Detailed
Executive Vice President and Chief Information Officer/Chief Technology Officer
BS
Bryan Smith
Detailed
Executive Vice President and Chief People Officer
JS
Jeremy Skule
Detailed
Executive Vice President and Chief Strategy Officer; Executive Chair, Financial Crime Management Technology
JZ
John Zecca
Detailed
Executive Vice President and Chief Legal, Risk and Regulatory Officer
MD
Michelle Daly
Detailed
Senior Vice President and Controller and Principal Accounting Officer
NG
Nelson Griggs
Detailed
President
SY
Sarah Youngwood
Detailed
Executive Vice President and Chief Financial Officer
TC
Tal Cohen
Detailed
President
Board of directors at NASDAQ.
AZ
Alfred Zollar
Detailed
Director
CB
Charlene Begley
Detailed
Director
EK
Essa Kazim
Detailed
Director
HS
Holden Spaht
Detailed
Director
JY
Jeffery Yabuki
Detailed
Director
JT
Johan Torgeby
Detailed
Director
KK
Kathryn Koch
Detailed
Director
MA
Melissa Arnoldi
Detailed
Director
MS
Michael Splinter
Detailed
Lead Independent Director
TK
Thomas Kloet
Detailed
Director
TT
Toni Townes-Whitley
Detailed
Director
Research analysts who have asked questions during NASDAQ earnings calls.
Alexander Blostein
Goldman Sachs
8 questions for NDAQ
Also covers: AB, AMG, AMP +31 more
Brian Bedell
Deutsche Bank
7 questions for NDAQ
Also covers: AMG, AMTD, APO +24 more
Michael Cyprys
Morgan Stanley
7 questions for NDAQ
Also covers: AAMI, AMP, AMTD +30 more
Ashish Sabadra
RBC Capital Markets
6 questions for NDAQ
Also covers: ADP, ADT, CBOE +21 more
Benjamin Budish
Barclays PLC
6 questions for NDAQ
Also covers: AB, APO, ARES +24 more
OL
Owen Lau
Oppenheimer & Co. Inc.
6 questions for NDAQ
Also covers: BLSH, CLVT, CME +9 more
PM
Patrick Moley
Piper Sandler & Co.
6 questions for NDAQ
Also covers: BGC, CBOE, CME +17 more
AK
Alex Kramm
UBS Group AG
5 questions for NDAQ
Also covers: BR, CBOE, CBRE +16 more
DF
Dan Fannon
Jefferies & Company Inc.
5 questions for NDAQ
Also covers: AB, AMG, AMTD +26 more
JS
Jeff Schmitt
William Blair & Company, L.L.C.
5 questions for NDAQ
Also covers: AIZ, AMP, CBOE +11 more
MC
Michael Cho
JPMorgan Chase & Co.
5 questions for NDAQ
Also covers: ENV, FHI, FRGE +4 more
EA
Eli Abboud
Bank of America
4 questions for NDAQ
Also covers: BGC, CBOE, CME +2 more
SC
Simon Clinch
Redburn Atlantic
4 questions for NDAQ
Also covers: CME, EFX, FICO +4 more
Craig Siegenthaler
Bank of America
3 questions for NDAQ
Also covers: AB, AMP, AMTD +26 more
DF
Daniel Fannon
Jefferies Financial Group Inc.
3 questions for NDAQ
Also covers: AB, AMG, AMTD +28 more
Kyle Voigt
Keefe, Bruyette & Woods
3 questions for NDAQ
Also covers: AMTD, APO, ARES +17 more
AK
Alexander Kramm
UBS Group AG
2 questions for NDAQ
WK
William Katz
TD Cowen
2 questions for NDAQ
Also covers: AB, AMG, AMTD +25 more
YC
Y. Cho
JPMorgan Chase & Co.
2 questions for NDAQ
Also covers: LPLA
Ben Budish
Barclays PLC
1 question for NDAQ
Also covers: AB, APO, ARES +23 more
Brian Bertram Bedell
Deutsche Bank AG
1 question for NDAQ
CA
Christopher Allen
Citigroup
1 question for NDAQ
Also covers: CBOE, CME, ETOR +9 more
JS
Jeffrey Schmitt
William Blair
1 question for NDAQ
Also covers: AIZ, AMP, CBOE +8 more
KS
Kwun Sum Lau
Oppenheimer
1 question for NDAQ
Also covers: CBOE, CLVT, CME +9 more
SA
Simon Alistair Clinch
Redburn Atlantic
1 question for NDAQ
Also covers: CME, EFX, FICO +3 more
Recent press releases and 8-K filings for NDAQ.
New Era Energy & Digital files FY 2025 Form 10-K
NDAQ
New Projects/Investments
- New Era Energy & Digital, Inc. (Nasdaq: NUAI) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The company will host a business update conference call and webcast on Tuesday, March 17, 2026, at 5:00 p.m. ET to review recent developments and strategic priorities.
- New Era is developing Texas Critical Data Centers LLC (TCDC), a 438-acre AI and high-performance computing data center campus in Ector County, Texas, master-planned to scale to over 1 GW of capacity.
- The vertically integrated model offers powered land and powered shells, enabling hyperscale, enterprise, and edge operators to accelerate deployments and optimize total cost of ownership.
1 hour ago
Wealthfront reports Q4 and full-year 2026 results
NDAQ
Earnings
Share Buyback
Product Launch
- Record fourth-quarter revenue of $96.1 million (+16% YoY) and full-year revenue of $365.0 million (+18% YoY).
- Total Platform Assets reached $94.1 billion (up 17% YoY), with full-year net deposits of $6.7 billion.
- Non-GAAP Adjusted EBITDA of $170.7 million (47% margin) and free cash flow of $151.1 million, ending the year with corporate cash above $440 million; board authorized a $100 million share repurchase program.
- Expanded product suite with early access to Wealthfront Home Lending and launch of the proprietary Wealthfront Treasury Money Market Fund.
5 hours ago
Fitell rebrands as GMEX Robotics, ticker changes to GMEX
NDAQ
New Projects/Investments
- Fitell Corporation (NASDAQ: FTEL) announces its rebrand to GMEX Robotics, marking a strategic shift from fitness equipment e-commerce to AI-powered consumer and commercial robotics; legal name change effective March 2, 2026.
- The company’s Nasdaq ticker will change from FTEL to GMEX at market open on March 12, 2026; no shareholder action is required and the CUSIP remains unchanged.
- GMEX Robotics will continue its fitness and health product business as a core foundation while focusing on three pillars: consumer/commercial robotics, AI-driven hardware, and an interconnected innovation ecosystem.
- To drive this strategic pivot, GMEX Robotics is assembling a new leadership team and technical workforce specializing in mechatronics, computer vision, and machine learning.
13 hours ago
Eagle Nuclear Energy joins Uranium Producers of America
NDAQ
- Eagle Nuclear Energy Corp. (NASDAQ: NUCL) became a member of the Uranium Producers of America, the leading domestic uranium trade association advocating for a secure U.S. nuclear fuel supply chain.
- According to the U.S. Energy Information Administration, the U.S. relies on imports for 95% of its uranium, with domestic production projected at 1 million pounds in 2026 versus the 50 million pounds needed annually.
- The company began trading publicly on Nasdaq under the ticker NUCL in February 2026, marking its entry into the U.S. nuclear development sector.
- Eagle owns the largest conventional U.S. uranium deposit, with the Aurora Project containing 32.75 million pounds Indicated and 4.98 million pounds Inferred near-surface resources, plus the adjacent Cordex deposit for further expansion.
1 day ago
Cullinan Therapeutics reports Q4 and full-year 2025 financial results and corporate update
NDAQ
Earnings
- Pipeline updates include Q2 2026 initial clinical data for CD19 T cell engager CLN-978 in SLE and RA, completion of Taiho’s rolling NDA submission for EGFR ex20ins inhibitor zipalertinib and full enrollment of the REZILIENT3 frontline NSCLC study (top-line results expected by end 2026), and planned CLN-049 registrational development in AML
- Cash position: ended 2025 with $439.0 million in cash, cash equivalents, investments, and interest receivable, providing runway into 2029
- Expenses: R&D expenses were $42.9 million in Q4 2025 (FY 2025: $187.4 million) and G&A expenses were $12.3 million in Q4 2025 (FY 2025: $54.2 million)
- Net loss attributable to Cullinan was $50.7 million for Q4 2025 and $219.9 million for full year 2025
1 day ago
Mineralys Therapeutics announces FDA acceptance of NDA for lorundrostat
NDAQ
Product Launch
- FDA accepted the New Drug Application for lorundrostat in adults with hypertension, assigning a PDUFA target action date of December 22, 2026.
- Phase 2 Explore-OSA topline results showed no meaningful reduction in apnea-hypopnea index but demonstrated an 11.1 mmHg blood pressure reduction with lorundrostat versus 1.0 mmHg with placebo (6.2 mmHg placebo-adjusted; p < 0.0003).
- Lorundrostat was well tolerated with no serum potassium excursions above 5.5 mmol/L in the trial population.
2 days ago
LifeMD reports fourth quarter and full year 2025 results
NDAQ
Earnings
Guidance Update
Product Launch
- Full year 2025 revenue grew 25% to $194.1 million, and adjusted EBITDA rose 309% to $15.3 million.
- Fourth quarter revenue increased 4% to $46.9 million, with adjusted EBITDA up 348% to $4.8 million.
- Exited 2025 with $36.8 million of cash and no debt, positioning the company for growth investments.
- Oral Wegovy launched subsequent to year end, with over 80% of new weight management patients initiating branded therapy and record Q1 sign-ups.
- 2026 guidance: expects full-year revenue of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million.
2 days ago
Nasdaq partners with Payward to develop xStocks-powered tokenized equity gateway
NDAQ
New Projects/Investments
Product Launch
- Nasdaq and Payward will build an xStocks-powered gateway to connect regulated equity markets with permissionless DeFi networks, enabling seamless tokenized equity transfers.
- Since its June 2025 launch, xStocks have recorded $25 billion in transaction volume and attracted 85,000 unique holders across supported blockchains.
- The gateway will facilitate swaps of tokenized equities between institutional trading environments and DeFi, with KYC/AML onboarding and Payward serving as the initial settlement layer.
- Nasdaq’s equity token design and related DLT services are expected to become operational in H1 2027, marking a significant step in equity tokenization.
3 days ago
NovaBridge reports positive VIS-101 Phase 2a results in wet AMD
NDAQ
- NovaBridge and Visara announced positive topline results from the randomized Phase 2a study of VIS-101, a dual VEGF-A × ANG-2 inhibitor for wet AMD, in 38 patients in China.
- VIS-101 achieved a mean improvement in BCVA of >10 ETDRS letters and a median CST reduction of 100–150 µm across 3 mg and 6 mg cohorts.
- Durability was notable, with ~two thirds of patients retreatment-free at 4 months and ~half retreatment-free at 6 months after three loading doses.
- The safety profile was favorable with no dose-limiting toxicity and only 8% treatment-related TEAEs in the 6 mg cohort.
- A dose-determining Phase 2b study is expected in H2 2026, followed by a global Phase 3 program in 2027.
3 days ago
ARS Pharma reports Q4 and FY2025 financial results and neffy commercialization progress
NDAQ
Earnings
Product Launch
- Total revenue of $28.1 M in Q4 and $84.3 M for full year 2025, driven by $72.2 M in U.S. neffy product sales.
- Net loss of $41.3 M (–$0.42 per share) in Q4 and $171.3 M (–$1.74 per share) for FY2025.
- Cash position of $245.0 M in cash, cash equivalents and short-term investments as of December 31, 2025, supporting operations through anticipated cash-flow break-even.
- U.S. commercial launch momentum: negotiating unrestricted payor access with $0 co-pay for eligible patients, coverage by eight state Medicaid plans, new DTC ad launched January 2026, and planned sales force expansion to 150 in Q2 2026.
- Global expansion advances with CHMP positive opinion for EUR neffy 1 mg (Jan 2026), approvals in China and Australia (Dec 2025), and Canada approval anticipated in Q2 2026.
3 days ago
Fintool News
In-depth analysis and coverage of NASDAQ.
Quarterly earnings call transcripts for NASDAQ.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more